WST Operating cash flow
Operating cash flow at West Pharmaceutical Services rose to $755M in fiscal 2025, from $653M in 2024.
Net cash provided by operating activities, as filed.
SOURCE: us-gaap:NetCashProvidedByUsedInOperatingActivities · EDGAR CompanyFacts · CIK 105770 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
FY2025$755M
FY2024 $653M
HIGH$776M FY2023
LOW$584M FY2021
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Operating cash flow | Change |
|---|---|---|
| FY2025 | $755M | +$101M |
| FY2024 | $653M | $-123M |
| FY2023 | $776M | +$52M |
| FY2022 | $724M | +$140M |
| FY2021 | $584M | — |
More SAME DATA, OTHER VIEWS
Operating cash flow across coverage → · WST company view →
Revenue · Net income · Free cash flow · Capital expenditure · Cash & equivalents · Total assets · Shareholders' equity · Total debt · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.